Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ultragenyx Pharma (RARE) PT Raised to $68 at Jefferies; Reiterates Hold
May 8, 2017 7:29 AM EDTJefferies raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $68.00 (from $66.00) while maintaining a Hold rating. 1Q expenses consisted of $51.3M R&D vs. $48.0M estimates, and $18.7M G&A vs. $20.2M.
Following recently reported ph.III KRN23 results in adult... More
Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c
May 4, 2017 4:46 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.63), $0.08 better than the analyst estimate of ($1.71).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More